EFTR — Effector Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.36m
- -$5.10m
Annual cashflow statement for Effector Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.7 | 14.2 | 15.8 | -22.7 | -35.8 |
| Depreciation | |||||
| Non-Cash Items | 0.763 | 0.288 | -40.5 | -5.96 | 4.46 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.07 | -0.824 | -0.238 | 2.68 | 1.69 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -27.6 | 13.8 | -24.9 | -25.9 | -29.6 |
| Capital Expenditures | -0.004 | -0.154 | -0.042 | -0.192 | -0.097 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.088 | 0 | 0.607 | -17.7 | 14.6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.084 | -0.154 | 0.565 | -17.9 | 14.5 |
| Financing Cash Flow Items | -0.093 | 0 | 52.9 | -0.037 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20.2 | -1.89 | 58.8 | 2.77 | 21.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -7.27 | 11.8 | 34.5 | -41 | 6.17 |